The recent news that the head of the Food and Drug Administration’s drug reviewing division had been ousted showed a federal health administration in chaos.
Yet a peek behind the main storyline reveals that something more troubling is happening. The Trump administration is turning drug review into make-a-deal. A new voucher program has created procedurally reckless sprints to market for companies that curry favor with the current administration or one of the health agencies.
STAT Pharma: The science and business of new drug development
Leave a Reply